Dr. Linda Robertson has over 15 years experience in pharmaceutical regulatory affairs in large global pharmaceutical and small biotechnology companies. She currently serves as a consultant providing regulatory expertise in international biologic and small molecule drug development, including strategic companion diagnostic development. She has expertise across a variety of therapeutic areas including oncology/hematology, rheumatology/autoimmune diseases, virology and neuropharmacology.
Previously Dr. Robertson served as a Senior Vice President at Ambit Pharmaceutical responsible for world-wide regulatory strategy and quality assurance for all Ambit products. Prior to Ambit she was Vice President, Regulatory Affairs and Quality Assurance at Kanisa Pharmaceuticals. She also served as Director, Drug Regulatory Affairs at Biogen IDEC, Inc. and its predecessor company, IDEC Pharmaceuticals with responsibilities for a variety of products including Rituxan®. Dr. Robertson began her career in industry at Roche Pharmaceuticals. During her tenor at Roche she held various senior Regulatory Affairs positions at Palo Alto, California and Nutley, New Jersey where she led the US approval of Tamiflu®.
Dr. Robertson received her Ph.D. in neurobiology from Northwestern University in Evanston, Illinois, and additional post-doctoral training in molecular biology from the Roche Institute of Molecular Biology in Nutley, New Jersey. She received a B.A. in biology from Lewis and Clark College in Portland, Oregon.